Dr. Mamatha Bhat is a Hepatologist and leads the Transplant AI initiative at the University Health Network's Ajmera Transplant Centre, and Associate Professor of Medicine at the University of Toronto. Dr. Bhat completed her medical school and residency training at McGill University. She then completed a Transplant Hepatology fellowship at the Mayo Clinic in Rochester, Minnesota, followed by a Canadian Institutes of Health Research (CIHR) Fellowship for Health Professionals, through which she completed a PhD. The goal of Dr. Bhat’s research program is to improve long-term outcomes of liver transplantation through a precision medicine approach. Her program is unique in using tools of Artificial Intelligence with bioinformatics to personalize the care of liver transplant recipients based on an improved biological understanding of the liver and disease after transplant. Her interdisciplinary program has been supported by the Canadian Institutes for Health Research (CIHR), Canadian Donation and Transplant Research Program (CDTRP), Natural Sciences and Engineering Research Council (NSERC), Canadian Liver Foundation (CLF), among others. Dr. Bhat is Partnership & Engagement Lead for the Temerty Centre for AI Research and Education in Medicine (T-CAIREM), Chair of the International Liver Transplant Society Basic and Translational Science Research committee; on the Executive committee of the CDTRP, and an Associate Editor for the American Journal of Transplantation. Dr. Bhat has also been the recipient of recognitions such as the 2022 CIHR-INMD-CASL Early Career Researcher prize, CASL Research Excellence award and the 2021 American Society of Transplantation Basic Science Career Development Award.

Mayur Brahmania is an Associate Clinical Professor at the University of Calgary in the Division of Gastroenterology and Transplant medicine. Mayur has been involved with the Choosing Wisely Canada (CWC) campaign as the Canadian Association for the Study of Liver Quality Lead where he led the development of the 'top 5' list recommendations for Hepatology and his group is currently working to develop strategies to benchmark quality indicators for chronic liver disease and HCC across Canada.

Prof. Vogel is a clinician scientist at the rank of a full professor at the University of Toronto, Canada. His scientific focus is the translational and clinical research in gastrointestinal cancer. Since 2004, he is leading a translational research group interested in the pathogenesis of hepatobiliary cancers and in precision medicine. Arndt Vogel is a clinical investigator in oncology since 2006. He is author or co-author of more than 310 articles published in peer-reviewed journals including Lancet, Lancet Oncology, Cancer Cell, and Gastroenterology among others. Prof. Vogel is member of societies including ESMO, ASCO, and EASL. He is member and chairman of Hepatobiliary Cancer Study Group of the AIO, a collaborative group in clinical oncology in Germany. Within ESMO, he is member of the ESMO Guidelines Steering Committee. He has responsibilities in the establishment of the national guideline and is the coordinator of the ESMO clinical practice guideline on the management of hepatocellular carcinoma and biliary tract cancer.

Xun Zhao received his MD from McGill University and has completely residency in internal medicine and gastroenterology at McGill University Health Center followed by a two-year fellowship at the University Health Network in liver transplantation and hepatocellular carcinoma. He is currently pursuing a PhD in clinical epidemiology at the University of Toronto under the co-supervision of Dr. Mamatha Bhat. He is also an attending hepatologist at the McGill University Health Center.